Interferon lambda as a potential treatment for COVID-19.
Expert Opin Biol Ther
; 23(5): 389-394, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-37147857
ABSTRACT
INTRODUCTION:
Pegylated interferon lambda substantially reduced the risk of COVID-19-related hospitalizations or emergency room visits in a recent phase 3, multi-center, randomized, double-blind, placebo-controlled study of high-risk, non-hospitalized adult patients with SARS-CoV-2 infection compared to treatment with placebo. AREAS COVERED Interferons are a family of signaling molecules produced as part of the innate immune response to viral infections. The administration of exogenous interferon may limit disease progression in patients with COVID-19. EXPERT OPINION Interferons have been used to treat viral infections, including hepatitis B and hepatitis C, and malignancies such as non-Hodgkin's lymphoma, as well as the autoimmune condition multiple sclerosis. This manuscript examines what is known about the role of interferon lambda in the treatment of COVID-19, including potential limitations, and explores how this approach may be used in the future.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Virus Diseases
/
COVID-19
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
Expert Opin Biol Ther
Journal subject:
BIOLOGIA
/
TERAPEUTICA
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos